# A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)

> **NCT05075824** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 95 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Crovalimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05075824
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-09
- **Primary completion:** 2025-06-11
- **Final completion:** 2026-04-09
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05075824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05075824, "A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05075824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*